MoonLake Immunotherapeutics (MLTX) to Release Earnings on Tuesday

MoonLake Immunotherapeutics (NASDAQ:MLTX) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect MoonLake Immunotherapeutics to announce earnings of ($0.90) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 12:30 PM ET.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.07). On average, analysts expect MoonLake Immunotherapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

MoonLake Immunotherapeutics Stock Down 3.2%

NASDAQ:MLTX traded down $0.63 during midday trading on Tuesday, reaching $19.25. The company had a trading volume of 98,850 shares, compared to its average volume of 1,487,356. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -4.97 and a beta of 1.04. The stock’s fifty day simple moving average is $19.04 and its 200-day simple moving average is $17.76. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The company has a current ratio of 8.60, a quick ratio of 8.60 and a debt-to-equity ratio of 0.39.

Insiders Place Their Bets

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 68,289 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $20.02, for a total value of $1,367,145.78. Following the sale, the chief executive officer directly owned 2,774,893 shares in the company, valued at $55,553,357.86. This trade represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $19.43, for a total value of $971,500.00. Following the sale, the insider directly owned 2,824,551 shares of the company’s stock, valued at $54,881,025.93. This trade represents a 1.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 250,000 shares of company stock worth $4,919,138. 10.40% of the stock is owned by insiders.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its holdings in MoonLake Immunotherapeutics by 18,782.8% in the fourth quarter. Janus Henderson Group PLC now owns 2,095,988 shares of the company’s stock valued at $27,657,000 after purchasing an additional 2,084,888 shares in the last quarter. Logos Global Management LP acquired a new stake in MoonLake Immunotherapeutics during the fourth quarter worth approximately $23,065,000. Vivo Capital LLC acquired a new stake in MoonLake Immunotherapeutics during the fourth quarter worth approximately $13,180,000. Schonfeld Strategic Advisors LLC acquired a new stake in MoonLake Immunotherapeutics during the third quarter worth approximately $6,922,000. Finally, Millennium Management LLC lifted its position in shares of MoonLake Immunotherapeutics by 709.4% during the 4th quarter. Millennium Management LLC now owns 802,722 shares of the company’s stock worth $10,580,000 after buying an additional 703,550 shares during the last quarter. Hedge funds and other institutional investors own 93.85% of the company’s stock.

Wall Street Analysts Forecast Growth

MLTX has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 12th. Needham & Company LLC boosted their price objective on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. BTIG Research restated a “buy” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of MoonLake Immunotherapeutics in a report on Monday, July 20th. Finally, Leerink Partners lifted their price target on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and a consensus target price of $24.21.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.